1 Both COVID-19 infection and vaccination induce high-affinity cross-

2 clade responses to SARS-CoV-2 variants

- 3
- 4 Marc Emmenegger¹, Sebastian Fiedler², Silvio D. Brugger³, Sean R. A. Devenish², Alexey S. Morgunov^{2,4},
- 5 Alison Ilsley², Francesco Ricci², Anisa Y. Malik², Thomas Scheier³, Leyla Batkitar¹, Lidia Madrigal¹, Marco
- 6 Rossi⁵, Andrew K. Lynn², Lanja Saleh⁵, Arnold von Eckardstein⁵, Tuomas P. J. Knowles^{2,4,6}, Adriano
- 7 Aguzzi^{1&}
- 8 ¹ Institute of Neuropathology, University of Zurich, 8091 Zurich, Switzerland
- ² Fluidic Analytics, Unit A, The Paddocks Business Centre, Cherry Hinton Road, Cambridge CB1 8DH, United
 Kingdom
- ³ Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich,
 Zurich, Switzerland
- ⁴ Centre for Misfolding Diseases, Yusuf Hamied Department of Chemistry, University of Cambridge, Lensfield
 Road, Cambridge CB2 1EW, United Kingdom
- 15 ⁵ Laboratory Medicine, University Hospital Zürich, Switzerland
- ⁶ Cavendish Laboratory, Department of Physics, University of Cambridge, JJ Thomson Ave, Cambridge, CB3 OHE,
 United Kingdom
- 18 & Corresponding author: <u>adriano.aguzzi@usz.ch</u>
- 19

20 Abstract

21 The B.1.1.529 (omicron) variant has rapidly supplanted most other SARS-CoV-2 variants. Using 22 microfluidics-based antibody affinity profiling (MAAP), we have recently shown that current 23 therapeutic monoclonal antibodies exhibit a drastic loss of affinity against omicron. Here, we have 24 characterized affinity and IgG concentration in the plasma of 39 individuals with multiple trajectories 25 of SARS-CoV-2 infection and/or vaccination as well as in 2 subjects without vaccination or infection. 26 Antibody affinity in patient plasma samples was similar against the wild-type, delta, and omicron variants (K_A ranges: 122±155, 159±148, 211±307 μ M⁻¹, respectively), indicating a surprisingly broad 27 28 and mature cross-clade immune response. We then determined the antibody iso- and subtypes 29 against multiple SARS-CoV-2 spike domains and nucleoprotein. Postinfectious and vaccinated subjects 30 showed different profiles, with IgG3 (p = 0.002) but not IgG1, IgG2 or IgG4 subtypes against the spike 31 ectodomain being more prominent in the former group. Lastly, we found that the ELISA titers against the wildtype, delta, and omicron RBD variants correlated linearly with measured IgG concentrations 32 33 (R=0.72) but not with affinity (R=0.29). These findings suggest that the wild-type and delta spike 34 proteins induce a polyclonal immune response capable of binding the omicron spike with similar 35 affinity. Changes in titers were primarily driven by antibody concentration, suggesting that B-cell 36 expansion, rather than affinity maturation, dominated the response after infection or vaccination.

37

38 Key words

39 SARS-CoV-2 B.1.1.529, Omicron, antibody affinity, antibody typing, exploratory data analysis

41 Introduction

The SARS-CoV-2 B.1.1.529 variant (omicron), considered a WHO variant of concern due to its high 42 transmission rate and its large number of mutations (Han et al., 2022), has become the predominant 43 44 viral lineage across the globe in early 2022. Its 34 mutations in the spike protein, 15 of which are located within its receptor binding domain (RBD) which interacts with ACE2, have been shown to 45 impact neutralization (1) of the rapeutic monoclonal antibodies in pseudotyped virus-based assays 46 47 (Cao et al., 2021; Cele et al., 2021; Planas et al., 2021; VanBlargan et al., 2022), (2) of serum antibodies of convalescent patients infected with previous strains, and (3) of serum antibodies of double-48 49 vaccinated individuals who had been vaccinated with BNT162b2 (Pfizer-BioNTech), mRNA-1273 50 (Moderna), Ad26.COV2.S (Johnson & Johnson), ADZ1222 (Astra Zeneca), Sputnik V, or BBIBP-CorV 51 (Sinopharm) (Planas et al., 2021; Cameroni et al., 2022; Dejnirattisai et al., 2022; Edara et al., 2022; 52 Liu et al., 2022). While triple vaccination with BNT162b2 or mRNA-1273 or a combination between infection with WT or delta SARS-CoV-2 followed by vaccination increased neutralizing potency 53 54 compared to double-vaccinated or convalescent serum, titers were still drastically lower for omicron 55 compared with WT or delta SARS-CoV-2 (Planas et al., 2021; Cameroni et al., 2022; Dejnirattisai et al., 56 2022; Edara et al., 2022; Liu et al., 2022).

The antibody response against one or multiple epitopes, elicited upon infection or vaccination is 57 58 characterized by two properties: affinity and concentration. Those are fundamental, well-defined 59 biophysical parameters; however, until recently it has been challenging to measure them directly in 60 complex heterogeneous mixtures, like serum or plasma. We have recently employed Microfluidic 61 Antibody Affinity Profiling (MAAP) to simultaneously determine the affinity and concentration of 62 antibodies against WT RBD in convalescent sera (Schneider et al., 2022), to study the antibody-based 63 inhibition of RBD-ACE2 interactions (Fiedler et al., 2021) and to understand memory re-activation and 64 cross-reactivity (Denninger et al., 2021). We have also characterized the affinity of multiple therapeutic antibodies (cilgavimab, tixagevimab, casirivimab, and imdevimab) to the omicron RBD 65 66 variant (Fiedler et al., 2022). While most of these antibodies exhibited a striking loss of affinity, a 67 pooled plasma standard of anti-SARS-CoV-2 immunoglobulins (Mattiuzzo et al., 2020) retained substantial cross-reactivity to the omicron spike RBD with only moderately decreased antibody 68 69 concentration and affinity against the omicron variant (Fiedler *et al.*, 2022).

Here, we determined the antibody fingerprints in 39 pre-omicron and two uninfected/non-vaccinated control patients admitted to the University Hospital Zurich, Switzerland. Patients included in this study had a variety of disease trajectories (including no COVID-19) and had received between zero and three doses of vaccine. Using MAAP, we first analyzed antibody affinity and concentration against WT, delta, and omicron RBD variants. We then assessed the impact of vaccination or infection, alone or in 75 combination, as well as of other parameters such as age or disease severity, to antibody concentration 76 and affinity. Lastly, we characterized the antibody isotype and subtype compositions against SARS-CoV-2 spike domains and against the nucleocapsid (NC) protein using a miniaturized enzyme-linked 77 78 immunoassay (ELISA) for SARS-CoV-2 antigens called TRABI (Emmenegger et al., 2020, 2021). We 79 found that the natural humoral responses of pre-omicron patients showed less severe reductions of 80 antibody affinity than was observed with monoclonal antibodies and we speculate that this is due to 81 the polyclonal nature of the infection- or vaccination-induced humoral immune response. Additionally, we found that ELISA-based antibody titers correlated with IgG concentrations but not 82 83 with affinity, and the antibody profiles in vaccinated but non-infected patients were different from 84 those of patients with a history of SARS-CoV-2 infection.

86 Results

- 87 Study design and experimental approach.
- 88 We have recently described a powerful microfluidics-based technology that enables the affinity
- determination of complex antibody mixtures in solution in plasma samples (Schneider *et al.*, 2022).
- 90 Our finding that affinity of therapeutic monoclonal antibodies are markedly decreased against the
- 91 SARS-CoV-2 omicron RBD variant (Fiedler et al., 2022) prompted us to investigate the anti-omicron
- 92 affinity of serum responses in patients who had suffered from pre-omicron COVID-19, or were
- 93 vaccinated with pre-omicron vaccines.



Figure 1. Study design and experimental approach. A. Flowchart for inclusion and exclusion into the study. 41 samples were included in the analysis, representing different patient groups. B. Violin boxplot showing distribution of IgG $p(EC_{50})$ values against the SARS-CoV-2 spike protein. A cutoff value of $p(EC_{50}) \ge 2$ was chosen to define reactive samples. Blue dots represent samples of infected and/or vaccinated individuals. Yellow dots are non-infected and non-vaccinated negative controls.

94 We collected heparin plasma samples of 50 individuals (pre-omicron) admitted to our hospital. One 95 sample was hemolytic and was excluded from further analyses (Fig. 1A). Forty-nine samples were tested for IgG reactivity against the SARS-CoV-2 WT spike protein using the TRABI technology 96 97 (Emmenegger *et al.*, 2020, 2021). We set a cutoff of $p(EC_{50}) \ge 2$ for inclusion in subsequent analyses. Eight samples did not reach this threshold and were excluded (Fig. 1B). The remaining 41 samples 98 99 comprised two patients without prior infection/vaccination, eight patients who had suffered SARS-100 CoV-2 infection but had not received any vaccination, 20 patients who had never been infected with 101 SARS-CoV-2 but received vaccinations (BNT162b2 or mRNA-1273) and 11 patients with previous SARS-102 CoV-2 infection and vaccination (see Table 1). The presence of infection, prior or at the time of sampling, was inferred based on medical history and/or one or multiple positive SARS-CoV-2 RT-qPCR. 103 The median age of enrolled patients was 65 (interquartile range (IQR): 54-77) years. Among the 104 105 patients with a history of infection (n=19), the median days post-onset of disease manifestation (DPO)



Figure 2. Characterization of affinity of SARS-CoV-2 antibodies to WT, delta, and omicron RBD variants. A. 2D scatter plot with integrated density contours. All quantifiable data points reflecting K_A (in M⁻¹) and IgG concentration values (in M) are plotted. 95% confidence intervals for each point are colored in light red. Triangles denote patients receiving the REGN-COV cocktail. RBD variants: WT (grey), delta (blue), omicron (yellow). Dotted lines represent the measurements of the same patient sample against different RBD variants. **B.** Bar graph displaying the percentages of quantifiable samples for WT (grey), delta (blue), and omicron (yellow) RBD variants. **Comparisons were performed including all samples, samples excluding those treated with REGN-COV, and only those treated with REGN-COV.** Fisher's exact test displayed no significant differences, at $\alpha = 0.01$. **C-D.** Boxplot analysis of K_A values (C) and IgG concentration, we utilized the product $K_A \times IgG$ concentration. C-E: Colors denote treatment with REGN-COV (red) or absence of treatment (blue). Kruskal-Wallis (KW) with post-hoc Wilcoxon rank sum test (WC) after Holm correction for multiple comparisons was used, with $\alpha = 0.01$. None of the group-wise comparisons reached statistical significance.

was 12 (IQR: 8.25-17.75) days. For five patients whose infection dated back more than a month before
sampling, the exact DPO could not be inferred from the clinical record. These samples were analyzed
using MAAP (Denninger *et al.*, 2021; Fiedler *et al.*, 2022; Schneider *et al.*, 2022) with SARS-CoV-2
wildtype (WT), delta, and omicron RBD variants. Antibody isotypes and subtypes were further
assessed in the same samples using TRABI (Emmenegger *et al.*, 2020, 2021).

111 Characterization of affinity of SARS-CoV-2 antibodies to WT, delta, and omicron RBD

112 variants.

- 113 We measured the affinities and concentrations of patient samples to WT, delta, and omicron RBD. We
- 114 report the affinity constant (K_A), which is $1/K_D$, where K_D is the equilibrium dissociation constant.
- 115 Measured antibody affinity constants ranged between 3.59 μM⁻¹ (*K*_D: 278 nM, i.e. comparatively low

affinity) and 943.3 μ M⁻¹ (K_D : 1 nM, i.e. comparatively high affinity). Thus, we observed an approximately 250-fold affinity range within our cohort. The IgG concentrations varied between 3 and 49,074 nM (range: 4.2 log₁₀) (**Fig. 2A**). The integrated 2D-density plot revealed a moderate left shift, i.e. overall decreased K_{A_1} of antibodies to omicron while none of the variants formed separate clusters



Figure 3. Correlation of affinity and IgG concentrations with clinically relevant parameters does not reveal clear differences between vaccinated and infected subgroups. A. 2D scatter plot with integrated density contours. All quantifiable data points reflecting K_A (in M⁻¹) and IgG concentration (in M) are plotted. 95% confidence intervals for each point are colored in light red. No distinct clusters were observed among patient groups infected/vaccinated (grey), infected/non-vaccinated (blue), non-infected/vaccinated (yellow), however, the REGN-COV-treated patients (red) clustered separately. B. The same groups as in (A) depicted in a boxplot. Statistical analysis is shown in the graph. The RBD variants are color-coded. C and D. No correlation between age (C) or sex (D) and $K_A \times IgG$ concentration. E. While Kruskal-Wallis statistical testing indicates that the distributions are significantly different for different disease severities, pair-wise testing with Wilcoxon rank sum test does not result in significance. F. Trend towards increased $K_A \times IgG$ concentration products in triple vaccinated individuals, without being statistically significant. A: Dotted lines represent the measurements of the same patient sample against different RBD variants. B, D-F: Kruskal-Wallis (KW) with post-hoc Wilcoxon rank sum test (WC) after Holm correction for multiple comparisons was used, with $\alpha = 0.01$. C: The Pearson correlation coefficient was calculated. C-F: The patient groups are color-coded as in (A), however, the REGN-COV-treated patients were excluded from analyses.

and mostly overlapped. 49% of samples could not be quantified in terms of K_A or IgG concentration for omicron (33% for wildtype and 36% for delta) (**Fig. 2B**). However, the distributional differences of quantifiable/non-quantifiable samples did not significantly differ (Fisher's exact test, $\alpha = 0.01$) among any of the antigens, for all samples (n=39), for those with an exclusively infection- and/or vaccineinduced antibody response (n=34), or for those treated with the REGN-COV cocktail (casirivimab and imdevimab, n=5), although a trend towards increased evasion of antibody binding for omicron was visible.

127 We then investigated K_A (Fig. 2C), IgG concentrations (Fig. 2D) and the product of $K_A \times IgG$ 128 concentration (Fig. 2E) for the three RBD variants. None of the variants displayed a statistically 129 significant deviation (Kruskal-Wallis with post-hoc Wilcoxon rank sum test after Holm correction for 130 multiple comparisons, with α = 0.01). Five patients who received the REGN-COV antibody cocktail 131 displayed the highest IgG concentrations measured, yet their affinities were in the range of the non-REGN-COV-treated patients (Fig. 2A, 2C-E). In sum, the antibody response following infection and/or 132 133 vaccination appears less susceptible to a drastic loss in binding against the omicron variant compared 134 to monoclonal antibodies.

135 Correlation of antibody fingerprints with clinically relevant parameters does not reveal136 clear differences between vaccinated and infected subgroups.

137 We next characterized the affinity/concentration profiles in four patient groups: (1) infected/non-138 vaccinated; (2) non-infected/vaccinated; (3) infected/vaccinated; (4) treated with REGN-COV. We 139 studied the same profile as above, but we color-coded the data points according to the groups of 140 patients (Fig. 3A). The patients treated with the REGN-COV cocktail clustered separately as expected, 141 whereas the density representations for vaccinated and/or infected patient groups were largely 142 overlapping. Statistical testing showed that the $K_A \times IgG$ concentration product significantly differed in patients treated with the REGN-COV cocktail versus all other groups (Wilcoxon rank sum test after 143 144 Holm correction, Fig. 3B). However, the profiles observed following vaccination and/or infection did not statistically differ among each other. In the following analyses, we have focused solely on those 145 146 groups with physiological antibody responses and excluded the REGN-COV-treated patients. 147 Correlations of K_A x IgG concentration with age (Fig. 3C, the Pearson correlation coefficient R was 148 calculated for the three groups), sex (Fig. 3D) or with disease severity (Fig. 3E) revealed heterogeneity 149 rather than marked differences. The Kruskal-Wallis test indicated significant distributional differences 150 as a function of disease severity (p-value=0.0084), yet, pair-wise testing with Wilcoxon rank sum test did not result in any significantly changed group after correcting for multiple comparisons. While we 151 observed a trend towards increased $K_A \times IgG$ concentration with a higher number of vaccinations (Fig. 152 153 3F), the distributions did not significantly differ. In conclusion, multiple vaccinations and the

- 154 combinations of infections and vaccinations do not exert an immediately measurable effect on
- 155 fundamental biophysical properties such as K_A and IgG concentrations in the complex samples used in
- this study.



Figure 4. Analysis of antibody subtypes, correlation with MAAP parameters, and global feature profiling. A. Multiple heatmaps. Purple heatmap displaying $p(EC_{50})$ values (gradient) obtained with TRABI ELISA, for IgG, IgA, IgM, IgG1, IgG2, IgG3, IgG4 antibodies. The SARS-CoV-2 WT spike ectodomain, the WT S1 domain, the WT S2 domain, the WT RBD, the delta RBD, and the omicron RBD variants as well as the nucleocapsid (NC) proteins were used. Orange heatmap displaying K_A values, green heatmap displaying IgG concentration, grey heatmap displaying K_A x IgG concentration obtained with MAAP against WT, delta, and omicron RBD variants. Additional heatmaps depict the age (red to blue), sex (orange: male; blue: female), number of vaccinations (yellow=0, orange=1, purple=2, red=3), treatment with the REGN-COV cocktail (green=TRUE), the strength of immunosuppression (none=light blue, slight=turquoise, heavy=darkblue), the days post onset of infection (DPO) for patients with infection (pink), and disease severity (orange gradient). **B**. Correlation between IgG $p(EC_{50})$ values of the spike ectodomain with K_A , IgG concentrations, or the product K_A x IgG concentration. **C**. Principal component analysis using all TRABI ELISA values as input. The three plots represent different color-based clustering approaches.

157 Analysis of antibody subtypes, correlation with affinity and global feature profiling.

As infection, vaccination or parameters such as disease severity, age, and number of vaccinations did not clearly correlate with antibody affinity or concentration, we aimed to obtain a more granular view of the antibody compositions. Thus, we used TRABI (Emmenegger *et al.*, 2020, 2021) to deeply characterize the antibody iso- and subtypes in our patient collective, to compare it to antibody affinity and concentration, and to seek potential clinical or demographic correlates.

- 163 We first measured IgG, IgA, IgM, IgG1, IgG2, IgG3, and IgG4 antibodies against the SARS-CoV-2 WT 164 spike ectodomain (ECD), the WT S1 domain, the WT S2 domain, the WT RBD, the delta RBD, and the 165 omicron RBD variants as well as the nucleocapsid (NC) proteins and illustrate them in a heatmap (Fig. 166 **4A**, purple gradients). The antibody profile mainly revealed that the antibody response, in general, is 167 dominated by IgG, followed by IgA and much less so by IgM and that all IgG subtypes, except IgG2, contributed to the IgG response against the spike-associated domains (Fig. S1A). The presence of IgG 168 169 antibodies against the NC, the only protein employed here that is not intrinsically connected to the spike ECD, is indicative of an infection, which was observed in almost all patients with clinically 170 171 characterized infection with SARS-CoV-2. For NC, the dominant IgG subtype was IgG3 (Fig. S1B).
- 172 To validate our results, we repeated the IgG4 measurements against the entire collection of antigens, 173 with the same IgG4-specific secondary antibody (Fig. S1C) and with the same clone but different 174 storage buffer sold by a different vendor (Fig. S1D). We observed robust correlations using the same 175 IgG4-specific secondary antibody (Pearson correlation coefficient R=0.94) as well as the same antibody 176 clone from a different source (Pearson correlation coefficient R=0.93) in three fully independent 177 experiments. Moreover, the IgG titers measured for the three RBD variants via ELISA correlated well 178 among each other (Fig. S2A-C) and with the spike protein (Fig. S2D) Similarly, the immunoglobulin iso-179 and subtype compositions have been largely congruent for the three RBD variants, as shown using the 180 mean p(EC₅₀) values (Fig. S2E).

181 We then included additional features such as the K_A values, the IgG concentrations, age, sex, 182 indications for treatment with REGN-COV antibodies, immunosuppression (none, light, heavy), the 183 DPO as well as disease severity, and aligned these values for each patients, separated into the vaccination/infection groups (Fig. 4A). This view offers a comprehensive multidimensional assessment 184 of many parameters at the single-individual level. We first correlated the IgG ELISA $p(EC_{50})$ values 185 obtained against WT, delta, and omicron RBD with the respective MAAP-derived K_{A} , the IgG 186 187 concentration, and the product K_A x IgG concentration (Fig. 4B, and Fig. S3 for a general representation). While K_A showed no linear relationship with ELISA titers (average R over all 188 189 groups=0.29, p-value=0.015), both IgG concentration (average R over all groups=0.72, p-value=5.4 x

10⁻¹³) as well as the MAAP product (average R over all groups=0.71, p-value=5.4 x 10⁻¹²) were well
 represented by a linear model, for all the three variants. This finding suggested that the titers observed
 in ELISA primarily reflect antibody concentrations rather than affinities in samples analyzed here.

193 We then reduced the dimensionality across all measured antibodies using principal component 194 analysis (PCA) and projected the linear combinations in two-dimensional space (Fig. 4C, and Fig. S4 195 for a granular view on the variable map). We used three representations using colors and shapes: (1) 196 The infection/vaccination cohorts, where we included patients treated with the REGN-COV antibodies, 197 (2) the number of vaccinations (excluding REGN-COV), (3) disease severity (excluding REGN-COV). 198 Regional clusters of specific antibody iso- and subtypes were annotated in black. Black shapes indicate 199 the mean points of a given group (indicated by color and shape). PCA suggested that while patients 200 with infection (infected/non-vaccinated; infection/vaccinated) clustered towards spike-associated 201 (annotated as S*) IgG3 as well as NC IgG, IgG1, IgG3, and IgA, patients with vaccination (non-202 infected/vaccinated: infected/vaccinated) clustered towards spike-associated IgG4. Spike-associated 203 IgG as well as IgG1 were between the two groups. Moreover, a higher number of vaccinations (two or 204 three) appeared to be linked to spike-associated IgG4 positivity, while fewer vaccinations (none or 205 one) clustered more closely to spike-associated IgG3 as well as to NC IgG, IgG1, IgG3, and IgA. A largely 206 similar pattern was observed with disease severity. No or mild disease clustered more in the region of 207 spike-associated IgG4 while more severe disease courses (hospitalization, oxygen supplementation, 208 ICU) assembled in the region of spike-associated IgG3 and the NC sub- and isotypes referred to above. 209 In sum, this representation evidenced an association between infection, more severe disease, absence 210 of vaccinations, and an IgG3 response against the spike-associated proteins. Conversely, the IgG4 211 response against spike-associated proteins was mainly characterized by vaccination, with higher 212 repeats of vaccinations, and a less severe disease course on average.

213 Multidimensional analysis suggests slightly different antibody profiles in patients after

214 SARS-CoV-2 infection versus vaccination alone.

Based on the patterns identified above, we analyzed potential associations using different methods. 215 216 We first calculated the Pearson correlation coefficients for all antigens and antibody iso- and subtypes 217 and included additional parameters such as disease severity, immunosuppression, the REGN-COV 218 cocktail, the number of vaccinations, sex, and age, and plotted the significant correlations in a 219 correlogram (Fig. 5A). Globally, the correlogram indicated a pronounced positive correlation within 220 the iso- or subtypes, which is expected as all domains are contained within the spike ECD, except the NC antigen. IgG1 correlated almost perfectly with IgG, while IgM and IgG2 displayed only spurious 221 222 correlation with IgG. Disease severity correlated with reactivity against the NC protein, for IgG, IgA, 223 IgG1, and foremostly IgG3 but not for IgG2 or IgG4. A higher number of vaccinations showed negative

- 224 correlations with NC for IgA and IgG1. Sex and age did not display strong correlations in any direction.
- The same correlogram with all correlations irrespectively of the significance level is shown in Fig. S5.





226 We then looked into the antibody reactivity profiles that have shown relevance based on the PCA 227 representation and the correlogram. The $p(EC_{50})$ values of seven Ig iso- and subtypes for the SARS-228 CoV-2 spike ECD were represented as a ridge plot. We focused only on the spike protein as a well-229 correlated surrogate for other spike domains (see Fig. S2D), and omitted the NC protein from this 230 analysis. We compared the groups per antibody iso- and subtype looking at the entire distribution by 231 means of Kruskal-Wallis test with post-hoc Wilcoxon rank sum test corrected for multiple comparisons 232 with Holm (α =0.01). Exclusively significant distributional differences were annotated in the in the plot 233 (see Fig. 5B). Kruskal-Wallis statistics indicated that the IgG responses of the non-infected/vaccinated 234 groups showed a significant change among each other (p-value=0.0024), however, the group-wise 235 testing by means of the Wilcoxon rank sum test did not reach statistical significance due to multiple comparisons that were performed. Likewise, the IgG distributions differed among the degrees of 236 237 severity (p-value=0.0076, Kruskal-Wallis), but pair-wise testing resulted in non-significant differences 238 While the IgG4, but not overall IgG, IgG1, IgG2, or IgG3 distributions of patients after vaccination 239 showed a trend towards higher $p(EC_{50})$ values, which were increased after three vaccinations, this 240 observation did not reach statistical significance. However, infection was associated with higher p(EC₅₀) values for IgG (p-value=0.00028, Wilcoxon rank sum test after Holm correction), and IgG3 (p-241 242 value=0.002, Wilcoxon) but not for IgG1, IgG2 or IgG4.

244 Discussion

We reported that the monoclonal antibodies deployed against previous variants of SARS-CoV-2 show drastically reduced affinity against the omicron variant (Fiedler *et al.*, 2022). Here, we found that deltainfected and/or vaccinated subjects develop plasma antibodies with similar affinities to all major SARS-CoV-2 clades. Previous SARS-CoV-2 infection (alone or in combination with vaccination), but not vaccination alone, was associated with higher overall anti-SARS-CoV-2 spike IgG, and IgG3 titers. Thus, although antibody profiles following infection differs from that of vaccinated patients who did not encounter the virus, pre-omicron responses showed impressive cross-clade affinities.

- 252 The high-affinity responses to the omicron spike protein contrast starkly with those of current 253 therapeutic monoclonal antibodies (Fiedler et al., 2022) whose neutralization of omicron was poor or 254 absent (Dejnirattisai et al., 2021; Planas et al., 2021; VanBlargan et al., 2022). The K_A of plasma antibodies against SARS-CoV-2 RBD variants were in a similar range of 16.9-684.9 μ M⁻¹ for WT, 13.5-255 256 471.7 μ M⁻¹ for delta, and 3.6-943.4 μ M⁻¹ for omicron. These data may provide an explanation for the 257 observation that patient sera after three doses of the Pfizer-BioNTech mRNA vaccine and convalescent 258 individuals after a Pfizer-BioNTech booster retained neutralization capacity against omicron (Planas et 259 al., 2021).
- As expected, the spike-specific IgG concentrations of the REGN-COV cocktail administered to patients exceeded the IgG concentrations following a genuine immune response triggered by infection or vaccination by approximately 30-fold and the K_A x IgG concentration product was significantly different in the group treated with REGN-COV versus all other groups. However, we did not identify any significant correlate between K_A or IgG concentrations and parameters such as infection or vaccination, alone or in combination, the number of vaccinations, the severity of disease, or with sex and age.

267 To increase the depth in our data set, we added data complementary to antibody affinity and 268 concentrations and mapped the contributions of different iso- and subtypes measured by TRABI ELISA 269 (Emmenegger et al., 2020, 2021), using a comprehensive panel of antigens (WT spike ectodomain, WT 270 spike S1, WT spike S2, WT RBD, delta RBD, omicron RBD, NC protein). We observed that the $p(EC_{50})$ 271 values of the RBD variants derived by ELISA correlated well with each other, in line with affinity 272 measurements, as well as with the WT spike. However, while ELISA titers correlated poorly with 273 affinity measurements, they were in excellent agreement with the IgG concentrations. Hence antibody 274 titers measured in ELISA, typically a conflation of both affinity and concentration, were mostly driven 275 by concentrations rather than affinities. Most likely this is because at an estimated ELISA plate surface-276 bound RBD concentration of about 480 nM, the expected [antibody-RBD] complex concentration is 277 much more sensitive to antibody concentration than to antibody affinity, provided that antibody 278 concentrations exceed K_D . At low affinities (high K_D values) close to the measured antibody 279 concentration or if the antibody concentrations drop to about the K_D or lower, the [antibody-RBD] 280 complex concentration becomes much more sensitive to affinity. At a mean K_D of 6 nM and IgG 281 concentration of 1 μ M in our dataset (across all RBD variants measured), our immobilization-based 282 ELISA measurements are thus mostly influenced by antibody concentration.

283 Several patients had IgG4 antibody titers against spike domains, but not against the NC, a 284 phenomenon which had not been reported to the same extent (Amanat et al., 2020; Suthar et al., 285 2020; Klingler et al., 2021; Kober et al., 2022; Sievers et al., 2022) although IgG4 antibodies against spike domains have been reported (Farkash et al., 2021; Jarlhelt et al., 2021). Our observation was 286 287 corroborated by repeating the measurements using the same IgG4-specific secondary antibody as well 288 as by using the same clone from an alternative source (including differences in concentrations and 289 storage buffers), which makes us confident that the results presented are valid. The higher prevalence 290 of the IgG4 subtype might arise due to repeated encounters with the antigen, which earlier studies 291 may not have captured.

292 We next explored the antibody profiles using a feature-based dimensionality reduction and 293 comprehensive correlograms. Both approaches pointed towards a slightly altered antibody profile 294 following vaccination or infection, with a stronger IgG3 response upon infection. However, the clusters 295 were relatively weak and potentially ambiguous in our dataset, although a previous investigation 296 derived similar conclusions regarding differences in the profiles between vaccinated and convalescent 297 individuals (Klingler et al., 2021). Therefore, we focused on WT spike ECD, by looking at the distribution 298 in a statistical manner. We confirmed that infection alone or in combination with vaccination was 299 associated with higher $p(EC_{50})$ values for IgG and IgG3 but not for IgG1, IgG2 or IgG4.

The limitations of our investigations reside in the number of patients enrolled in the study and the vast number of variables reported, which may constrain the generalizability of results and conclusions. Therefore, all variables underlying this study are available for further studies and for comparison with future cohorts. On the other hand, our findings describing the antibody response of pre-omicron convalescent or post-vaccination sera to the SARS-CoV-2 omicron variant are congruent with those found by others with other methods, including viral neutralization and clinical observations.

In conclusion, we have investigated antibody affinity and concentration following infection and/or vaccination in the presence of an antigenic drift. We found that the tolerance to the omicron drift was surprisingly robust, whereas the currently approved therapeutic monoclonal antibodies lost much of their affinity. The most plausible scenario is that antibodies are selected in vivo for immunodominant

- 310 spike domains that are invariant between clades of virus, whereas therapeutic monoclonals were
- 311 presumably selected in vitro for highest affinity but not for cross-clade protection. Ultimately, our
- 312 finding, along with others, suggests that the B-cell-mediated immunity, possibly concomitant with a
- 313 T-cell response, elicited upon infection and/or vaccination might be broad enough to confer a layer of
- 314 protection in the event of further waves of mutated SARS-CoV-2 variants.

316 Methods and Materials

317 Ethics statement.

For this study, we included residual pre-omicron heparin plasma samples from patients admitted to 318 319 the University Hospital Zurich, Zurich, Switzerland, whose blood was sent to the Institute of Clinical 320 Chemistry for routine diagnostic procedures. Infections with the SARS-CoV-2 B.1.1.529 variant were 321 excluded by means of dropout PCR. All experiments and analyses involving samples from human donors were conducted with the approval of the ethics committee of the canton Zurich, Switzerland 322 323 (KEK-ZH-Nr. 2015-0561, BASEC-Nr. 2018-01042, and BASEC-Nr. 2020-01731), in accordance with the 324 provisions of the Declaration of Helsinki and the Good Clinical Practice guidelines of the International 325 Conference on Harmonisation. All subjects enrolled in the study signed the hospital-wide General 326 Consent of the University Hospital Zurich, Switzerland.

327 Fluorescent labeling of proteins

Recombinant proteins were labeled with Alexa Fluor 647 NHS ester (Thermo Fisher) as described previously (Fiedler *et al.*, 2021, 2022). In brief, solution containing 150 µg of spike RBD was mixed with dye at a three-fold molar excess in the presence of NaHCO3 (Merck) buffer at pH 8.3 and incubated at 4 °C overnight. Unbound label was removed by size-exclusion chromatography (SEC) on an ÄKTA pure system (Cytiva) using a Superdex 75 Increase 10/300 column (Cytiva). Labeled and purified proteins were stored at -80 °C in PBS pH 7.4 containing 10% (w/v) glycerol as cryoprotectant.

Antibody affinity and concentration determination.

335 Microfluidic Antibody Affinity Profiling (MAAP) measurements were performed as reported previously (Schneider et al., 2022). For the MAAP measurements, varying fractions of human plasma samples 336 337 were added to a solution of the antigen of concentrations varying between 1 nM and 400 nM, and a 338 buffer containing PBS at pH 7.4, 0.05% (w/v) Tween 20 (Merck), 5% (w/v) human serum albumin 339 (Merck), and 10% (w/v) glycerol (Merck). The antigens used were RBD (Sino Biological; WT 40592-V08H, Delta 40592- V08H90, Omicron 40592- V08H121) labelled with Alexa Fluor[™] 647 (Thermo 340 Fisher) through amine coupling. These samples were incubated on ice for 30 minutes and the size of 341 the formed immunocomplex was determined through measuring the hydrodynamic radius, $R_{\rm h}$, with 342 343 Microfluidic Diffusional Sizing (MDS) using the commercial Fluidity One-M platform. The data were 344 analysed by Bayesian inference as described previously (Linse et al., 2020; Schneider et al., 2022).

345 ELISA.

Serological ELISAs were carried out as previously described (Emmenegger *et al.*, 2020, 2021) with
 minor adjustments. High-binding 1,536-well plates (Perkin-Elmer; SpectraPlate 1536 HB) were coated
 with 3 μL of 1 μg/mL SARS-CoV-2 spike ECD, WT S1, WT S2, WT RBD, delta RBD, omicron RBD, or NC
 protein in PBS using Fritz Gyger Certus Flex, incubated at 37 °C for 1 h in a ThermoFisher rotating plate

350 incubator, and washed three times with PBS 0.1% Tween-20 (PBS-T) using Biotek El406. Plates were 351 blocked with 10 µL of 5% milk in PBS-T for 1.5 h using Biotek Multiflo FX peristaltic dispensing 352 technology. Samples inactivated with 1% Triton X-100 and 1% tributyl phosphate were diluted in 353 sample buffer (1% milk in PBS-T), and a serial dilution (range: 0.02 to 1.6×10^{-4}) was carried out 354 (volume: 3 µL per well) on an ECHO 555 acoustic dispenser (Labcyte) using contactless ultrasound 355 nanodispensing. After the sample incubation for 2 h at RT, the wells were washed five times with wash buffer, and the presence of anti–SARS-CoV-2 antibodies was detected using horseradish peroxidase 356 357 (HRP)-linked antibodies (1. anti-human IgG antibody: Peroxidase AffiniPure Goat Anti-Human IgG, Fcy 358 Fragment Specific; Jackson; 109-035-098 at 1:4,000 dilution. 2. anti-human IgA antibody: Goat Anti-359 Human IgA Heavy Chain Secondary Antibody, HRP; Thermo Fisher Scientific; 31417 at 1:750 dilution. 360 3. anti-human IgM antibody: anti-human IgM μ -chain–specific antibody; Sigma-Aldrich; A6907 at 361 1:3,000 dilution. 4. anti-human IgG1 antibody: mouse anti-human IgG1 Fc-HRP; Southern Biotech; 362 9054-05 at 1:3,000 dilution. 5. anti-human IgG2 antibody: mouse anti-human IgG2 Fc-HRP; Southern 363 Biotech; 9060-05 at 1:3,000 dilution. 6. anti-human IgG3 antibody: mouse anti-human IgG3 Hinge-364 HRP; Southern Biotech; 9210-05 at 1:3,000 dilution. 7. anti-human IgG4 antibody: mouse anti-human IgG4 Fc-HRP; Southern Biotech; 9200-05 at 1:3,000 dilution), all of them diluted in sample buffer at 3 365 366 µL per well dispensed on Biotek Multiflo FX. The incubation of the secondary antibody for 1 h at RT 367 was followed by three washes with PBS-T, the addition of 3 µL per well of Tetramethylbenzidine (TMB) 368 substrate solution with a Fritz Gyger Certus Flex dispenser, incubation of 3 min at RT, and the addition 369 of 3 μ L per well 0.5 M H₂SO₄ using Fritz Gyger Certus Flex. The plates were centrifuged in the Agilent 370 automated microplate centrifuge after all dispensing steps, except for the addition of TMB. The 371 absorbance at 450 nm was measured in a plate reader (Perkin-Elmer; EnVision), and the inflection 372 points of the sigmoidal binding curves [i.e., the $p(EC_{50})$ values of the respective sample dilution; $p(EC_{50})$ 373 is the negative logarithm of one-half the maximal concentration (EC_{50}) were determined using a 374 custom-designed fitting algorithm (Emmenegger et al., 2020), with plateau and baseline inferred from 375 the respective positive and negative controls in a platewise manner. Negative p(EC₅₀) values, reflecting nonreactive samples, were rescaled as zero. 376

For quality testing, the same procedure was applied as above using the same clone (HP6025) of the
HRP-linked secondary antibody but from a different vendor, including a different storage buffer:
mouse anti-human IgG4; Invitrogen; A-10654 at 1:500 dilution.

380 Statistics and data analysis.

When looking at continuous distributions, tests were performed using the compare_means() function of the ggpubr package 0.4.0 in R. The method chosen was Kruskal-Wallis (method=kruskal.test) with subsequent Wilcoxon rank sum test (method=wilcox.test) with Holm correction for multiple

comparisons, comparing groups with $\alpha < 0.01$ for Kruskal-Wallis against all other groups. Comparisons where $\alpha < 0.01$ with Wilcoxon rank sum test were annotated. Fisher's test was conducted in Graph Pad Prism, with $\alpha < 0.01$.

Principal component analysis was performed using the prcomp() function as a part of the stats (version 3.6.2) package in R, with center = TRUE und scale = FALSE. The data was then visualised using fviz_pca_biplot() from the factoextra library. The correlation matrix was computed using the cor() function (part of the stats (version 3.6.2) package) in R and visualised as a correlogram using the corrplot() function in the corrplot package in R. The p-values of the correlations were computed using the cor.test() function (part of the stats (version 3.6.2) package) for the Pearson correlation coefficient and $\alpha < 0.01$ was chosen for significance.

For visualisation of individual data points in boxplots, violin plots, ridge plots (ggridges package), density plots (with geom_density_2d where a 2D kernel density estimation was performed on the X and Y coordinates of the input data and the results were displayed with contours), heatmaps (using heatmap.2, a part of the gplots 3.1.1 library), and as scatter dot plots, ggplot2 (version 3.3.5) functions were used. Regression lines and 95% confidence intervals were calculated in ggplot2 and regression coefficients were computed using the stat_cor() function a part of the ggpbubr (version 0.4.0) package. Radar plots were generated with the fmsb package (version 0.7.3) in R.

401 HRP-conjugated antibodies used.

402 See Table 2.

403 Table 2. HRP-conjugated antibodies used,

Species	Target	Dilution	Brand name	Product number
Goat	anti-human IgG	1:4,000	Jackson	109-035-098
Goat	anti-human IgA	1:750	Thermo Fisher Scientific	31417
Goat	anti-human IgM	1:3,000	Sigma-Aldrich	A6907
Mouse	anti-human lgG1	1:3,000	SouthernBiotech	9054-05
Mouse	anti-human IgG2	1:3,000	SouthernBiotech	9060-05
Mouse	anti-human IgG3	1:3,000	SouthernBiotech	9210-05
Mouse	anti-human IgG4	1:3,000	SouthernBiotech	9200-05
Mouse	anti-human lgG4	1:500	Invitrogen	A-10654

404

405 Antigens used.

406 See **Table 3**.

407 Table 3. Antigens used.

Antigen	Application	Source	Mutant amino acid residues	Coating concentration	Brand name/publication	Product number
					source	

spike ECD	ELISA	HEK293		1 μg /mL	(Emmenegger <i>et</i> <i>al.</i> , 2020), Oxford	
WT spike S1	ELISA	HEK293		1 μg /mL	AcroBiosystems	S1N- C52H2
WT spike S2	ELISA	HEK293		1 μg /mL	AcroBiosystems	S2N- C52H5
WT RBD	ELISA	HEK293		1 μg /mL	(Emmenegger <i>et</i> <i>al.</i> , 2020), Oxford	
WT RBD	ΜΑΑΡ	HEK293			Sino Biological	40592- V08H
Delta RBD	ELISA, MAAP	HEK293	L452R, T478K	1 μg /mL	Sino Biological	40592- V08H90
Omicron RBD	ELISA, MAAP	HEK293	G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H	1 μg /mL	Sino Biological	40592- V08H121
NC	ELISA	HEK293		1 μg /mL	AcroBiosystems	NUN- C5227

409 Supporting information

410 Acknowledgements

We are grateful to all the patients who enabled this study by means of signing the hospital-wide general consent and thereby contributed to scientific understanding. We thank the high-throughput serology team of the Institute of Neuropathology and the entire team of the Institute of Clinical Chemistry for help with sample handling and machine maintenance, Dr. Sreedhar Saseendran Kumar (BEL, ETH Zurich) for advice on statistical methods, Dr. Natascha Wuillemin (Mabylon AG, Schlieren) for the provision of a reagent, and Dr. Vishalini Emmenegger (BEL, ETH Zurich) for support and inspiration.

418 Funding statement

- Institutional core funding by the University of Zurich and the University Hospital of Zurich, Swiss
 National Science Foundation (SNF) grant #179040 as well as Driver Grant 2017DRI17 of the Swiss
- 421 Personalized Health Network to AA; funding by grants of Innovation Fund of the University Hospital
- 422 Zurich (INOV00096), and of the NOMIS Foundation, the Schwyzer Winiker Stiftung, and the Baugarten
- 423 Stiftung (coordinated by the USZ Foundation, USZF27101) to AA and ME as well as the USZ Foundation
- 424 USZF270808 to SDB.

425 Author contribution

- 426 Conceived the study: AKL, AA, SF, ME. Collected and annotated patient samples: SDB, TS, MR, LS, AvE,
- 427 ME. Performed MAAP experiments and analysed the respective data: SF, SRAD, ASM, FR, AI, AM, AKL,
- 428 TPJK. Performed TRABI experiments: LM, LB, AA, ME. Analysed the data: ME. Wrote the manuscript:
- 429 AA, ME. Read and revised the manuscript: all authors.

430 Competing Interest Statement

- 431 TPJK is a member of the board of directors of Fluidic Analytics. AA is a member of the clinical and
- 432 scientific advisory board of Fluidic Analytics. AA is a member of the board of directors of Mabylon AG.
- 433 AKL, SF, SRAD, ASM, AYM, AI, and FR are employees of Fluidic Analytics. All other authors declare no
- 434 competing interest.
- 435

436 References

Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T. H. O., Chromikova, V., McMahon, M., Jiang, K.,
Arunkumar, G. A., Jurczyszak, D., Polanco, J., *et al.* (2020) 'A serological assay to detect SARS-CoV-2
seroconversion in humans', *Nature Medicine*, 26(7), pp. 1033–1036. doi: 10.1038/s41591-020-09135.

Cameroni, E., Bowen, J. E., Rosen, L. E., Saliba, C., Zepeda, S. K., Culap, K., Pinto, D., VanBlargan, L. A.,
De Marco, A., di Iulio, J., *et al.* (2022) 'Broadly neutralizing antibodies overcome SARS-CoV-2
Omicron antigenic shift', *Nature*, 602(7898), pp. 664–670. doi: 10.1038/s41586-021-04386-2.

- Cao, Y., Wang, J., Jian, F., Xiao, T., Song, W., Yisimayi, A., Huang, W., Li, Q., Wang, P., An, R., *et al.*(2021) 'Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies', *Nature*.
 Available at: https://doi.org/10.1038/s41586-021-04385-3 (Accessed: 27 February 2022).
- Cele, S., Jackson, L., Khoury, D. S., Khan, K., Moyo-Gwete, T., Tegally, H., San, J. E., Cromer, D.,
 Scheepers, C., Amoako, D. G., *et al.* (2021) 'Omicron extensively but incompletely escapes Pfizer
 BNT162b2 neutralization', *Nature*. doi: 10.1038/S41586-021-04387-1.
- 450 Dejnirattisai, W., Huo, J., Zhou, D., Zahradník, J., Supasa, P., Liu, C., Duyvesteyn, H. M. E., Ginn, H. M.,
- 451 Mentzer, A. J., Tuekprakhon, A., et al. (2022) 'SARS-CoV-2 Omicron-B.1.1.529 leads to widespread
- 452 escape from neutralizing antibody responses', *Cell*, 185(3), pp. 467-484.e15. doi:
- 453 10.1016/J.CELL.2021.12.046.
- 454 Dejnirattisai, W., Shaw, R. H., Supasa, P., Liu, C., Stuart, A. S., Pollard, A. J., Liu, X., Lambe, T., Crook,
- D., Stuart, D. I., *et al.* (2021) 'Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by
 post-immunisation serum', *Lancet*, 399(10321), pp. 234–236. doi: 10.1016/s0140-6736(21)02844-0.
- 457 Denninger, V., Xu, C. K., Meisl, G., Morgunov, A. S., Fiedler, S., Ilsley, A., Emmenegger, M., Malik, A.
 458 Y., Piziorska, M. A., Schneider, M. M., *et al.* (2021) 'Understanding the role of memory re-activation
 459 and cross-reactivity in the defense against SARS-CoV-2', *bioRxiv*, p. 2021.07.23.453352. doi:
 460 10.1101/2021.07.23.453352.
- Edara, V. V., Manning, K. E., Ellis, M., Lai, L., Moore, K. M., Foster, S. L., Floyd, K., Davis-Gardner, M.
 E., Mantus, G., Nyhoff, L. E., *et al.* (2022) 'mRNA-1273 and BNT162b2 mRNA vaccines have reduced
 neutralizing activity against the SARS-CoV-2 omicron variant', *Cell Reports Medicine*, 3(2). doi:
 10.1016/j.xcrm.2022.100529.
- 465 Emmenegger, M., De Cecco, E., Lamparter, D., Jacquat, R. P. B., Ebner, D., Schneider, M. M.,
- 466 Condado Morales, I., Schneider, D., Dogancay, B., Guo, J., *et al.* (2020) 'Early peak and rapid decline 467 of SARS-CoV-2 seroprevalence in a Swiss metropolitan region', *medRxiv*. doi:
- 468 10.1101/2020.05.31.20118554.
- 469 Emmenegger, M., Saseendran Kumar, S., Emmenegger, V., Malinauskas, T., Buettner, T., Rose, L.,
- 470 Schierack, P., Sprinzl, M. F., Sommer, C. J., Lackner, K. J., *et al.* (2021) 'Anti-prothrombin
- autoantibodies enriched after infection with SARS-CoV-2 and influenced by strength of antibody
- 472 response against SARS-CoV-2 proteins', *PLOS Pathogens*, 17(12), p. e1010118. doi:
- 473 10.1371/JOURNAL.PPAT.1010118.
- 474 Farkash, I., Feferman, T., Cohen-Saban, N., Kirgner, I., Levin, Y., Dahan Correspondence, R., Avraham,
- 475 Y., Morgenstern, D., Mayuni, G., Barth, N., et al. (2021) 'Anti-SARS-CoV-2 antibodies elicited by
- 476 COVID-19 mRNA vaccine exhibit a unique glycosylation pattern', *Cell Reports*, 37. doi:
- 477 10.1016/j.celrep.2021.110114.
- Fiedler, S., Devenish, S. R. A., Morgunov, A. S., Ilsley, A., Ricci, F., Emmenegger, M., Kosmoliaptsis, V.,
 Theel, E. S., Mills, J. R., Sholukh, A. M., *et al.* (2022) 'Serological fingerprints link antiviral activity of

- therapeutic antibodies to affinity and concentration', *bioRxiv*, p. 2022.02.03.478946. doi:
 10.1101/2022.02.03.478946.
- 482 Fiedler, S., Piziorska, M. A., Denninger, V., Morgunov, A. S., Ilsley, A., Malik, A. Y., Schneider, M. M.,
- Devenish, S. R. A., Meisl, G., Kosmoliaptsis, V., *et al.* (2021) 'Antibody Affinity Governs the Inhibition
 of SARS-CoV-2 Spike/ACE2 Binding in Patient Serum', *ACS Infectious Diseases*, 7(8), pp. 2362–2369.
- 485 doi: 10.1021/acsinfecdis.1c00047.
- 486 Han, Pengcheng, Li, L., Liu, S., Wang, Q., Zhang, D., Xu, Z., Han, Pu, Li, X., Peng, Q., Su, C., *et al.* (2022)
- 487 'Receptor binding and complex structures of human ACE2 to spike RBD from omicron and delta
- 488 SARS-CoV-2', *Cell*, 185(4), pp. 630-640.e10. doi: 10.1016/J.CELL.2022.01.001.
- 489 Jarlhelt, I., Nielsen, S. K., Jahn, C. X. H., Hansen, C. B., Pérez-Alós, L., Rosbjerg, A., Bayarri-Olmos, R.,
- 490 Skjoedt, M. O. and Garred, P. (2021) 'SARS-CoV-2 Antibodies Mediate Complement and Cellular
- 491 Driven Inflammation', *Frontiers in Immunology*, 12, p. 4612. doi:
- 492 10.3389/FIMMU.2021.767981/BIBTEX.
- 493 Klingler, J., Lambert, G. S., Itri, V., Liu, S., Bandres, J. C., Enyindah-Asonye, G., Liu, X., Simon, V.,
- 494 Gleason, C. R., Kleiner, G., et al. (2021) 'Detection of Antibody Responses Against SARS-CoV-2 in
- 495 Plasma and Saliva From Vaccinated and Infected Individuals', *Frontiers in Immunology*, 12, p. 5382.
 496 doi: 10.3389/FIMMU.2021.759688/BIBTEX.
- 497 Kober, C., Manni, S., Wolff, S., Barnes, T., Mukherjee, S., Vogel, T., Hoenig, L., Vogel, P., Hahn, A.,
- 498 Gerlach, M., *et al.* (2022) 'IgG3 and IgM Identified as Key to SARS-CoV-2 Neutralization in
- 499 Convalescent Plasma Pools', *PLOS ONE*, 17(1), p. e0262162. doi: 10.1371/JOURNAL.PONE.0262162.
- Linse, S., Scheidt, T., Bernfur, K., Vendruscolo, M., Dobson, C. M., Cohen, S. I. A., Sileikis, E.,
- Lundqvist, M., Qian, F., O'Malley, T., *et al.* (2020) 'Kinetic fingerprints differentiate the mechanisms
 of action of anti-Aβ antibodies', *Nature Structural & Molecular Biology*, 27(12), pp. 1125–1133. doi:
 10.1038/s41594-020-0505-6.
- Liu, Lihong, Iketani, S., Guo, Y., Chan, J. F. W., Wang, M., Liu, Liyuan, Luo, Y., Chu, H., Huang, Yiming,
 Nair, M. S., *et al.* (2022) 'Striking antibody evasion manifested by the Omicron variant of SARS-CoV2', *Nature*, 602(7898), pp. 676–681. doi: 10.1038/s41586-021-04388-0.
- Mattiuzzo, G., Bentley, E. M., Hassall, M., Routley, S., Richardson, S., Bernasconi, V., Kristiansen, P.,
 Harvala, H., Roberts, D., Semple, M. G., *et al.* (2020) 'Establishment of the WHO International
 Standard and Reference Panel for anti-SARS-CoV-2 antibody', *World Health Organization*, 60.
- Planas, D., Saunders, N., Maes, P., Guivel-Benhassine, F., Planchais, C., Buchrieser, J., Bolland, W. H.,
 Porrot, F., Staropoli, I., Lemoine, F., *et al.* (2021) 'Considerable escape of SARS-CoV-2 Omicron to
- antibody neutralization', *Nature 2021 602:7898*, 602(7898), pp. 671–675. doi: 10.1038/s41586-02104389-z.
- 514 Schneider, M. M., Emmenegger, M., Xu, C. K., Morales, I. C., Meisl, G., Turelli, P., Zografou, C.,
- 515 Zimmermann, M. R., Frey, B. M., Fiedler, S., et al. (2022) 'Microfluidic characterisation reveals broad
- range of SARS-CoV-2 antibody affinity in human plasma', *Life Science Alliance*, 5(2), p. e202101270.
- 517 doi: 10.26508/LSA.202101270.
- 518 Sievers, B. L., Chakraborty, S., Xue, Y., Gelbart, T., Gonzalez, J. C., Cassidy, A. G., Golan, Y., Prahl, M.,
- 519 Gaw, S. L., Arunachalam, P. S., *et al.* (2022) 'Antibodies elicited by SARS-CoV-2 infection or mRNA
- 520 vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses', *Science*
- 521 *Translational Medicine*. doi: 10.1126/SCITRANSLMED.ABN7842.
- Suthar, M. S., Zimmerman, M. G., Kauffman, R. C., Mantus, G., Linderman, S. L., Hudson, W. H.,
 Vanderheiden, A., Nyhoff, L., Davis, C. W., Adekunle, O., *et al.* (2020) 'Rapid Generation of

- Neutralizing Antibody Responses in COVID-19 Patients', *Cell Reports Medicine*, 1(3), p. 100040. doi:
 10.1016/J.XCRM.2020.100040.
- 526 VanBlargan, L. A., Errico, J. M., Halfmann, P. J., Zost, S. J., Crowe, J. E., Purcell, L. A., Kawaoka, Y.,
- 527 Corti, D., Fremont, D. H. and Diamond, M. S. (2022) 'An infectious SARS-CoV-2 B.1.1.529 Omicron
- 528 virus escapes neutralization by therapeutic monoclonal antibodies', *Nature Medicine*, pp. 1–6. doi:
- 529 10.1038/s41591-021-01678-y.
- 530

- 532
- 533

534 Supplementary figure legends

535

Figure S1. Reactivity profile for Spike and NC and correlations between three repeat IgG4 536 537 measurements, using two different secondary antibodies. A. Violin plot showing the reactivity profile 538 for spike ECD. All IgG subtypes contribute to the reactivity, except IgG2. IgM are generally low. B. Violin 539 plot showing the reactivity profile for NC protein. The dominant subtype is IgG3. (A) and (B): 540 Infected/vaccinated patients are in grey, infected/non-vaccinated patients are in blue, and non-541 infected/vaccinated patients are in yellow. C. $p(EC_{50})$ values of the first IgG4 measurements versus 542 p(EC₅₀) values of the second IgG4 measurements. The same secondary antibodies were used. Data are pooled for all antigens. **D**. $p(EC_{50})$ values of the first IgG4 measurements versus $p(EC_{50})$ values of the 543 third IgG4 measurements. For the third measurement, a different secondary antibody was used. Data 544 545 are pooled for all antigens.

546

Figure S2. Correlations among RBD variants, the WT spike ectodomain, and comparison of RBD variants. A. p(EC₅₀) WT RBD versus p(EC₅₀) delta RBD. B. p(EC₅₀) WT RBD versus p(EC₅₀) omicron RBD.
 C. p(EC₅₀) delta RBD versus p(EC₅₀) omicron RBD. D. p(EC₅₀) WT spike ectodomain versus p(EC₅₀) WT

550 RBD. Shapes indicate the different patient groups. **E**. Mean $p(EC_{50})$ values of all immunoglobulin iso-

and subtypes for WT (grey), delta (blue), and omicron (yellow) RBD variants are shown in a radar plot.

552

Figure S3. Correlation of MAAP data with ELISA titers. K_A (A), IgG concentration (B), and the product of K_A x IgG concentration (C) were plotted against the respective ELISA p(EC₅₀) values obtained for WT, delta, and omicron RBD variants. The shapes indicate the respective patient groups, as is shown in the main figure.

557

Figure S4. Variables of PCA shown in main figure. The variables of the PCA representations from the
 main figures are displayed in detail. A. PCA including REGN-COV-treated patients. B. PCA excluding
 REGN-COV-treated patients.

561

Figure S5. Correlogram representation of all correlations without restriction by statistical significance. Correlogram analysis using the TRABI ELISA values combined with features such as disease severity, immunosuppression, number of vaccinations received, sex, and age.

565

567 Table 1. Basic demographic features of cohort.

	Ν	FEMALE	MALE	AGE (MEDIAN,	REGN-COV-
TABLE 1				IQR), YEARS	TREATED
ALL INDIVIDUALS	41	17	24	65, 54-77	5
NON-INFECTED/NON-	2	1	1	58.5, 58.25-58.75	0
VACCINATED					
INFECTED/NON-VACCINATED	8	4	4	61, 53-66	1
NON-INFECTED/VACCINATED	20	8	12	63, 57-78	0
INFECTED/VACCINATED	11	4	7	74, 61-84	4

568







Fig. S2









578